Global Blood Therapeutics
A clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities.
| EUR | 2017 | 2018 | 2019 | 2020 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | 100 % | 25 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (600 %) | (600 %) | (375 %) | (300 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (700 %) | (650 %) | (325 %) | (280 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Global Blood Therapeutics (GBT), now part of Pfizer, is dedicated to discovering, developing, and delivering innovative treatments for sickle cell disease (SCD), a lifelong inherited blood disorder affecting hemoglobin in red blood cells. GBT's core product, Oxbryta (voxelotor), has been approved by the U.S. FDA for SCD patients as young as 4 years old. The company operates in the biopharmaceutical sector, primarily serving patients, their families, and healthcare professionals. GBT's business model focuses on research and development, clinical trials, and regulatory approvals to bring new therapies to market. Revenue is generated through the sale of its approved treatments and potential future therapies. GBT is committed to changing the treatment paradigm in SCD through continuous innovation and strong community advocacy.
Keywords: sickle cell disease, biopharmaceutical, Oxbryta, voxelotor, FDA approval, innovative treatments, clinical trials, hemoglobin, inherited blood disorder, patient advocacy.